BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31881331)

  • 21. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
    Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
    Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clonal Hematopoiesis and Mosaicism Revealed by a Multi-Tissue Analysis of Constitutional TP53 Status.
    Castillo D; Yuan TA; Nehoray B; Cervantes A; Tsang KK; Yang K; Sand SR; Mokhnatkin J; Herzog J; Slavin TP; Hyman S; Schwartz A; Ebert BL; Amos CI; Garber JE; Weitzel JN
    Cancer Epidemiol Biomarkers Prev; 2022 Aug; 31(8):1621-1629. PubMed ID: 35654360
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer surveillance and distress among adult pathogenic TP53 germline variant carriers in Germany: A multicenter feasibility and acceptance survey.
    Rippinger N; Fischer C; Haun MW; Rhiem K; Grill S; Kiechle M; Cremer FW; Kast K; Nguyen HP; Ditsch N; Kratz CP; Vogel J; Speiser D; Hettmer S; Glimm H; Fröhling S; Jäger D; Seitz S; Hahne A; Maatouk I; Sutter C; Schmutzler RK; Dikow N; Schott S
    Cancer; 2020 Sep; 126(17):4032-4041. PubMed ID: 32557628
    [TBL] [Abstract][Full Text] [Related]  

  • 24. p53 major hotspot variants are associated with poorer prognostic features in hereditary cancer patients.
    Fortuno C; Pesaran T; Dolinsky J; Yussuf A; McGoldrick K; Kho PF; James PA; Spurdle AB
    Cancer Genet; 2019 Jun; 235-236():21-27. PubMed ID: 31296311
    [TBL] [Abstract][Full Text] [Related]  

  • 25.
    Terradas M; Mur P; Belhadj S; Woodward ER; Burghel GJ; Munoz-Torres PM; Quintana I; Navarro M; Brunet J; Lazaro C; Pineda M; Moreno V; Capella G; Evans DGR; Valle L
    Gut; 2021 Jun; 70(6):1139-1146. PubMed ID: 32998877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TP53 germline mutation testing in early-onset breast cancer: findings from a nationwide cohort.
    Bakhuizen JJ; Hogervorst FB; Velthuizen ME; Ruijs MW; van Engelen K; van Os TA; Gille JJ; Collée M; van den Ouweland AM; van Asperen CJ; Kets CM; Mensenkamp AR; Leter EM; Blok MJ; de Jong MM; Ausems MG
    Fam Cancer; 2019 Apr; 18(2):273-280. PubMed ID: 30607672
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fibroblast testing can inform medical management in individuals with mosaic variants detected on hereditary cancer panels.
    Sutcliffe EG; Mester JL; Susswein LR; Roberts ME; Marshall ML; Hruska KS
    Cancer Genet; 2022 Aug; 266-267():86-89. PubMed ID: 35926323
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genotype-phenotype correlations among TP53 carriers: Literature review and analysis of probands undergoing multi-gene panel testing and single-gene testing.
    Fortuno C; Pesaran T; Mester J; Dolinsky J; Yussuf A; McGoldrick K; James PA; Spurdle AB
    Cancer Genet; 2020 Oct; 248-249():11-17. PubMed ID: 32966936
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pediatric oncologist willingness to offer germline TP53 testing in osteosarcoma.
    Shaul E; Roth M; Lo Y; Geller DS; Hoang B; Yang R; Malkin D; Gorlick R; Gill J
    Cancer; 2018 Mar; 124(6):1242-1250. PubMed ID: 29313943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. From uncertainty to pathogenicity: clinical and functional interrogation of a rare
    Quinn EA; Maciaszek JL; Pinto EM; Phillips AH; Berdy D; Khandwala M; Upadhyaya SA; Zambetti GP; Kriwacki RW; Ellison DW; Nichols KE; Kesserwan C
    Cold Spring Harb Mol Case Stud; 2019 Aug; 5(4):. PubMed ID: 30886117
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TP53 variants of uncertain significance: increasing challenges in variant interpretation and genetic counseling.
    Bittar CM; Vieira IA; Sabato CS; Andreis TF; Alemar B; Artigalás O; Galvão HCR; Macedo GS; Palmero EI; Ashton-Prolla P
    Fam Cancer; 2019 Oct; 18(4):451-456. PubMed ID: 31321604
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Challenging interpretation of germline TP53 variants based on the experience of a national comprehensive cancer centre.
    Butz H; Bozsik A; Grolmusz V; Szőcs E; Papp J; Patócs A
    Sci Rep; 2023 Aug; 13(1):14259. PubMed ID: 37653074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study.
    Villani A; Shore A; Wasserman JD; Stephens D; Kim RH; Druker H; Gallinger B; Naumer A; Kohlmann W; Novokmet A; Tabori U; Tijerin M; Greer ML; Finlay JL; Schiffman JD; Malkin D
    Lancet Oncol; 2016 Sep; 17(9):1295-305. PubMed ID: 27501770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TP53 Variant in the Blood of a Patient with Gastric Cancer Undergoing Tumor Profiling Tests Diagnosed as Clonal Hematopoiesis.
    Kawai M; Iijima-Yamashita Y; Taguchi I; Kataoka M; Sanada M; Murakami Y; Kitagawa C; Hattori H
    Am J Case Rep; 2022 Jun; 23():e936455. PubMed ID: 35700150
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry.
    Yurgelun MB; Masciari S; Joshi VA; Mercado RC; Lindor NM; Gallinger S; Hopper JL; Jenkins MA; Buchanan DD; Newcomb PA; Potter JD; Haile RW; Kucherlapati R; Syngal S;
    JAMA Oncol; 2015 May; 1(2):214-21. PubMed ID: 26086041
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Whole-exome analysis of a Li-Fraumeni family trio with a novel TP53 PRD mutation and anticipation profile.
    Franceschi S; Spugnesi L; Aretini P; Lessi F; Scarpitta R; Galli A; Congregati C; Caligo MA; Mazzanti CM
    Carcinogenesis; 2017 Sep; 38(9):938-943. PubMed ID: 28911001
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes.
    Frebourg T; Bajalica Lagercrantz S; Oliveira C; Magenheim R; Evans DG;
    Eur J Hum Genet; 2020 Oct; 28(10):1379-1386. PubMed ID: 32457520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnosis of Li-Fraumeni Syndrome: Differentiating TP53 germline mutations from clonal hematopoiesis: Results of the observational AGO-TR1 trial.
    Weber-Lassalle K; Harter P; Hauke J; Ernst C; Kommoss S; Marmé F; Weber-Lassalle N; Prieske K; Dietrich D; Borde J; Pohl-Rescigno E; Reuss A; Ataseven B; Engel C; Stingl JC; Schmutzler RK; Hahnen E
    Hum Mutat; 2018 Dec; 39(12):2040-2046. PubMed ID: 30216591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional characterization of novel germline TP53 variants in Swedish families.
    Kharaziha P; Ceder S; Axell O; Krall M; Fotouhi O; Böhm S; Lain S; Borg Å; Larsson C; Wiman KG; Tham E; Bajalica-Lagercrantz S
    Clin Genet; 2019 Sep; 96(3):216-225. PubMed ID: 31081129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epithelioid angiomyolipoma of the liver in a patient with Li-Fraumeni syndrome: a case report.
    Yang Y; Lee J; Woo CG; Lee OJ; Son SM
    Diagn Pathol; 2024 Jan; 19(1):16. PubMed ID: 38243242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.